Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge.
BACKGROUND
Eosinophil peroxidase and myeloperoxidase halogenate tyrosine residues in plasma proteins and generate 3-bromotyrosine (BY) and 3-chlorotyrosine (CY), respectively.


OBJECTIVE
(1) To estimate urinary concentrations of BY and CY in asthmatic patients. (2) To investigate BY concentration in relation to urinary leukotriene E4 (LTE4) concentration in order to evaluate the activation of eosinophils in patients with aspirin-induced asthma (AIA).


METHODS
BY and CY were quantified with a gas chromatograph-mass spectrometer using (13)C-labelled compounds as internal standards.


RESULTS
(1) Activation of eosinophils and neutrophils by immobilized IgG1 induced preferential formation of BY and CY, respectively. (2) A significantly higher concentration of BY was observed in the urine from asthmatic patients than in that from healthy control subjects (45+/-21.7 vs. 22.6+/-10.8 ng/mg-creatinine, P<0.01). CY concentration was also elevated in the urine from asthmatic patients (4.4+/-3.2 vs. 1.5+/-1.0 ng/mg-creatinine, P<0.01). (3) After intravenous aspirin challenge of aspirin-induced asthmatic patients, the concentration of BY in urine did not significantly change. No significant change was also observed in the ratio of BY concentration to total tyrosine concentration in plasma proteins. In contrast, the concentration of urinary LTE4 significantly increased after the intravenous aspirin challenge.


CONCLUSIONS
Determination of BY and CY concentrations may be useful for monitoring the activation of eosinophils and neutrophils in asthmatic patients, respectively. After aspirin challenge of AIA patients, the increased concentration of urinary LTE4 did not accompany changes in BY concentration in both urine and plasma proteins. These results may preclude the activation of eosinophils after aspirin challenge in patients with AIA.
Mita
H
H
Clinical Research Center, National Sagamihara Hospital, Sagamihara, Kanagawa, Japan. h-mita@sagamihara-hosp.gr.jp
Higashi
N
N
Taniguchi
M
M
Higashi
A
A
Kawagishi
Y
Y
Akiyama
K
K
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin; D001249:Asthma / Q000276:immunology / Q000652:urine*; D001798:Blood Proteins / Q000737:chemistry; D001985:Bronchial Provocation Tests; D016022:Case-Control Studies; D004804:Eosinophils / Q000473:pathology; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D007958:Leukocyte Count; D017999:Leukotriene E4 / Q000652:urine; D009504:Neutrophils / Q000473:pathology; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000097:blood / Q000652:urine*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001798:Blood Proteins; D014443:Tyrosine; C118327:3-bromotyrosine; D017999:Leukotriene E4; D001241:Aspirin; C087259:3-chlorotyrosine